The Invisible Affliction: Why Africa's Neglected Tropical Diseases Demand a Human Rights Reckoning

The boy was twelve when trachoma stole his sight. In Karonga District, northern Malawi, the infection had progressed unchecked through years of inadequate water access and limited healthcare outreach. By the time a community health worker identified the advanced scarring, the damage was irreversible. He joined a caseload that the World Health Organization estimates at roughly 1.9 million people blinded or visually impaired by trachoma alone — a disease that, according to the evidence, should have been eliminated as a public health threat years ago.

That gap — between what medical science can accomplish and what vulnerable populations actually receive — lies at the heart of a debate gaining traction among public health practitioners across sub-Saharan Africa. The question is not whether interventions exist. It is whether the international system has a moral obligation to deliver them, and whether the current architecture of neglect constitutes a violation of the rights to health and to development.

A Disease Burden That Tracks Race and Geography

Neglected tropical diseases are, by definition, conditions that disproportionately affect the world's poorest people. The WHO's list of 21 conditions classified as NTDs — including trachoma, leishmaniasis, Chagas disease, and human African trypanosomiasis — maps almost perfectly onto nations that have historically received the least international development assistance for health. Sub-Saharan Africa carries the highest burden, accounting for roughly half of the global NTDcaseload despite representing only 14 percent of the world's population.

The epidemiological pattern is not accidental. Public health researchers and practitioners writing from within African institutions have pointed to a structural dynamic in which diseases perceived as affecting "others" — predominantly Black and brown populations in tropical zones — command far less research funding, pharmaceutical development attention, and political priority than conditions prevalent in wealthy nations. The pipeline for new NTD treatments has remained sparse: a 2023 review in The Lancet found that of the 1,556 new therapeutic agents approved globally between 2000 and 2021, only 21 were explicitly for an NTD. The economics of drug development do not reward investments in markets where patients cannot pay.

This is the context in which the human rights framing has emerged. Writing from Malawi's health system — where the author has served as clinician, public health officer, and head of national public health programming — advocates have argued that framing NTDs as a health problem alone has failed to generate the political urgency that mass disability and preventable mortality demand. A rights-based approach, they contend, imposes legal and moral obligations on governments and international institutions that charity and development assistance language has historically elided.

The Colonial Architecture of Global Health

The current architecture of NTD control was not designed by those it serves. The drugs, the delivery protocols, and the donor frameworks emerged predominantly from institutions in Europe and North America, often through mechanisms that prioritized the strategic interests of contributing governments over the expressed needs of endemic communities. Mass drug administration campaigns — distributing ivermectin, praziquantel, and azithromycin to hundreds of millions of people annually — have achieved genuine results. The WHO's NTD roadmap set targets for elimination as a public health problem for multiple diseases by 2030, and measurable progress has been made on trachoma, lymphatic filariasis, and schistosomiasis in several countries.

But the delivery model remains structurally dependent on donor generosity rather than enforceable entitlements. Countries like Malawi, where the health system operates under severe fiscal constraint, receive NTD medications primarily through donations from pharmaceutical companies — themselves facilitated by agreements negotiated at the global level. When supply chains falter, when funding cycles lapse, or when donor attention drifts toward newer crises, programs stall. The populations most exposed have no mechanism to compel continuation.

This dependency is not merely logistical. Critics of the current arrangement note that the language of "donations" and "access programs" subtly positions lifesaving medicine as a gift rather than an obligation — one that can be withdrawn at will. A human rights framework would reframe these interventions as components of the right to health recognized under international law, including the International Covenant on Economic, Social and Cultural Rights, which 171 states have ratified. Under that framework, the question shifts from "will donors continue to provide?" to "do affected populations have enforceable claims?"

What a Rights Framework Would Change

The practical implications of recognizing NTDs as a human rights issue are significant, even if the legal mechanisms for enforcement remain underdeveloped. At the national level, governments would face heightened obligations to integrate NTD care into primary health systems rather than relying on vertical, donor-driven campaigns. Water, sanitation, and hygiene infrastructure — the upstream determinants of most NTD transmission — would become rights-based claims rather than development aspirations. Civil society organizations would have standing to litigate gaps in coverage.

At the international level, a rights framing could alter the calculus of pharmaceutical research and development. The argument runs that states party to human rights covenants bear responsibility not only for ensuring access to existing medicines but for creating conditions in which necessary medicines are developed. This has implications for how research funding is allocated, how patent pools and compulsory licensing mechanisms are utilized, and how pharmaceutical companies are held accountable for neglecting diseases that primarily affect poor populations.

The evidence on what works is not disputed. The WHO has documented cost-effective interventions for all the major NTDs: mass drug administration, vector control, veterinary public health, and improved water and sanitation infrastructure. The cost of addressing the global NTD burden has been estimated at roughly $3.5 billion per year — a figure that represents less than 1 percent of what OECD nations spend annually on development assistance for health. The gap between what is possible and what is funded reflects political choice, not technical impossibility.

The Road Ahead

The human rights framing is not without its critics within the public health community. Some practitioners argue that framing NTDs as a rights issue risks politicizing technical interventions and alienating donors who prefer to operate outside legal frameworks. Others note that invoking rights claims without strengthening the enforcement mechanisms to back them may breed cynicism among affected populations who have watched previous commitments go unfulfilled.

These objections deserve serious engagement. But the alternative — continuing to treat mass disability and preventable death as a development afterthought — has produced seven decades of insufficient progress. The boy in Karonga did not lose his sight because medicine failed him. The tools to prevent trachoma blindness existed. The diagnostic capacity to catch it early existed. What did not exist, at the scale required, was the political will to deliver what was already available.

That gap is not a technical problem. It is a political one. And political problems, the evidence from global health history suggests, respond to pressure — including the pressure that comes from naming obligations clearly and refusing to let them dissolve into sentiment.

This publication covered the NTD human rights debate primarily through the lens of practitioner experience in Malawi, drawing on the author's account of working within that health system. Wire coverage from major health desks has tended to frame NTDs as a funding and logistics challenge rather than a rights entitlement — a distinction that itself reflects assumptions about which populations' suffering generates legal as opposed to charitable obligations.